EU Decision Time For Albireo’s Rare Liver Disease Drug
Odevixibat, which could become the first drug approved for treating progressive familial intrahepatic cholestasis in children, is up for an opinion from the European Medicines Agency.
You may also be interested in...
Yes Or No? Decisions Due On New EU Drug Applications
Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.
Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.
Rare Liver Disease Drug Contenders Among Latest EU Filings
Among the 13 new drug marketing applications that the European Medicines Agency has most recently accepted for review are two products that could become the first approved treatments for children with progressive familial intrahepatic cholestasis, a life-threatening disorder.